Office of Health Economics -
This report summarise research evaluating the main legal barriers to the better use of health data for pharmaceutical innovation. Issues are evaluated according to barriers arising in utilising data to support six key activities across the lifecycle of a medicine: epidemiology and pharmacoepidemiology: identifying unmet need; pharmacogenetics; interventional studies; non-interventional studies; pharmacovigilance; and managed entry agreements.